Beyond technical infrastructure, PFMG2025 relies on a set of transversal actions that are essential to ensuring the consistent and sustainable deployment of genomic medicine in France. These structural actions support the training of professionals, provide a framework for ethical and regulatory aspects, assess medico-economic impacts, mobilise the industrial ecosystem and strengthen international cooperation.
International affairs
PFMG2025 is part of an international context, benefiting from collaborations, benchmarks, feedback and shared standards.
These international affairs enable the French plan to be aligned with major genomic medicine initiatives around the world, to exchange best practices, to harmonise approaches, and to place French medical genomics within a global framework.
Initial and continuing training
The deployment of genomic medicine requires new skills across the entire care and research pathway — from prescription to reporting results, including bioinformatics, genetic analysis, ethics and patient counselling.
Ethics, regulation and society
The introduction of genomic sequencing in clinical practice—involving the collection, processing and storage of genetic data—raises major ethical, legal and societal issues. PFMG2025 therefore provides for in-depth reflection to ensure a framework that respects patients’ rights.
Medical and economic aspects
PFMG2025 incorporates a medical and economic dimension to assess the cost, value and impact of implementing very high-throughput genomic sequencing in the healthcare system.
Genomic medicine industrial sector
PFMG2025 defines an industrial sector dedicated to medical genomics that enables manufacturers (start-ups, SMEs, large companies) to integrate into the chain. This industrial dynamic aims to promote innovation, encourage the development of appropriate technologies, guarantee interoperability, data robustness and the upskilling of the entire ecosystem.